Blood test could spare stomach cancer patients from unnecessary chemo
NCT ID NCT07508956
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a simple blood test that detects tiny bits of tumor DNA (ctDNA) can help doctors decide which stomach cancer patients need extra chemotherapy after surgery. About 304 people with locally advanced stomach cancer will be randomly assigned to either standard care or treatment guided by the blood test. The goal is to see if this approach can reduce unnecessary treatments and side effects while keeping survival rates just as good.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC / GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Could a smartphone program supervised by AI boost recovery after stomach cancer surgery?
- Can stomach cancer surgery also tame diabetes?
- Can a modified stomach bypass speed up recovery in advanced gastric cancer?